Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Impact of early bacteremia on clinical outcomes following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based gvhd prophylaxis

Moazzam Shahzad, Shah Rukh, Aroog Khaliq, Aqeeb Ur Rehman, Amna Bint I Munir, Muhammad Kashif Amin, Amir Kasaeian, Anthony Sung, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

Blood (2025) 146 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2025-4200

Published: 2025

Journal Articles

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Blood (2025) 146 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2025-4198

Published: 2025

Journal Articles

Remote multi-vital sign monitoring allows earlier detection of cytokine release syndrome after bispecific T cell engager and chimeric antigen receptor T cell therapies

Blood (2025) 146 (Supplement 1): 1075.

https://doi.org/10.1182/blood-2025-1075

Published: 2025

Journal Articles

Vancomycin-resistant enterococci (VRE) colonization is associated with worse outcomes post allogenic hemopoietic stem cell transplantation

Haitham Abdelhakim, Abdalla Shoaib, Marwa Elsayed, Nadia Ghallab, Leyla Shune, Anurag Singh, Shaun DeJarnette, Anthony Sung, Joseph McGuirk, Sunil Abhyankar

Blood (2025) 146 (Supplement 1): 2501.

https://doi.org/10.1182/blood-2025-2501

Published: 2025

Journal Articles

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Blood (2025) 146 (Supplement 1): 818.

https://doi.org/10.1182/blood-2025-818

Published: 2025

Journal Articles

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Amy E. DeZern, MD, Anthony Sung, MD, Sharon Kim, MD, Hua-Ling Tsai, MS, Jeanne Kowalski, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Steven D. Gore, M.D., Ephraim Fuchs, MD, Michael A McDevitt, MD, PhD, Leo Luznik, MD, Richard J. Jones, MD, Mark J. Levis, MD, PhD

Blood (2010) 116 (21): 2172.

https://doi.org/10.1182/blood.V116.21.2172.2172

Published: 2010

Journal Articles

Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival.

Michael W Evans, MD, MPH, Anthony Sung, MD, Ivana Gojo, MD, Michael L Tidwell, RN, CRNP, Jacqueline Greer, RN, BSN, Mark Levis, Judith Karp, Maria R Baer, MD

Blood (2009) 114 (22): 4126.

https://doi.org/10.1182/blood.V114.22.4126.4126

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Impact of early bacteremia on clinical outcomes following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based gvhd prophylaxis

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Remote multi-vital sign monitoring allows earlier detection of cytokine release syndrome after bispecific T cell engager and chimeric antigen receptor T cell therapies

Vancomycin-resistant enterococci (VRE) colonization is associated with worse outcomes post allogenic hemopoietic stem cell transplantation

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival.

Email alerts

ASH Publications

American Society of Hematology

Update search

Impact of early bacteremia on clinical outcomes following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based gvhd prophylaxis

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Remote multi-vital sign monitoring allows earlier detection of cytokine release syndrome after bispecific T cell engager and chimeric antigen receptor T cell therapies

Vancomycin-resistant enterococci (VRE) colonization is associated with worse outcomes post allogenic hemopoietic stem cell transplantation

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only